General Information of Drug Combination (ID: DCDUNDR)

Drug Combination Name
Lenvatinib BN-2629
Indication
Disease Entry Status REF
Ewing sarcoma Investigative [1]
Component Drugs Lenvatinib   DMB1IU4 BN-2629   DMA9MP5
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: TC-71
Zero Interaction Potency (ZIP) Score: 19.726
Bliss Independence Score: 18.106
Loewe Additivity Score: 4.408
LHighest Single Agent (HSA) Score: 8.536

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Lenvatinib
Disease Entry ICD 11 Status REF
Thyroid cancer 2D10 Approved [2]
Thyroid gland follicular carcinoma N.A. Approved [3]
Thyroid gland papillary carcinoma N.A. Approved [3]
Hepatocellular carcinoma 2C12.02 Phase 3 [4]
Renal cell carcinoma 2C90 Phase 3 [5]
Melanoma 2C30 Phase 2 [4]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
Ovarian cancer 2C73 Phase 1 [6]
Non-small-cell lung cancer 2C25.Y Application submitted [5]
Lenvatinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Lenvatinib Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]
------------------------------------------------------------------------------------
Indication(s) of BN-2629
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [7]
BN-2629 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Binder [9]
------------------------------------------------------------------------------------
BN-2629 Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [10]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 208627.
3 Lenvatinib FDA Label
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
7 ClinicalTrials.gov (NCT02034227) Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia. U.S. National Institutes of Health.
8 Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci Rep. 2019 Apr 1;9(1):5404.
9 Single-Nucleotide Polymorphisms in Rv2629 Are Specific for Mycobacterium tuberculosis Genotypes Beijing and Ghana but Not Associated with Rifampin Resistance . J Clin Microbiol. 2009 January; 47(1): 223-226.
10 Optimization of the antitumor activity of sequence-specific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters. AAPS J. 2010 Dec;12(4):617-27.